louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01648491: Autologous Stem Cells for Urinary Incontinence: Single Patient Compassionate Use
Official title: Autologous Stem Cells for Urinary Incontinence: Single Patient Compassionate Use
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Stress Urinary Incontinence
Lead sponsor: William Beaumont Hospitals
Sponsor class: OTHER
Collaborators: name: William Beaumont Hospitals
First posted: 2012-07-24
Enrollment: 1
Sex: MALE
Minimum age (years): 78
Maximum age (years): 82
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Determine safety and effectiveness of the technique using autologous stem cells in the treatment of urinary incontinence in one male subject.

Detailed description: Autologous stem cells will be obtained from the subject by needle biopsy, sent to a lab for multiplication and after about 6 weeks time will be injected into the subjects urethra.

Eligibility criteria: Inclusion Criteria:

* urinary incontinence
* failed urinary incontinence (UI) treatments

Exclusion Criteria:

- does not meet inclusion criteria, gender and age limit

Primary outcomes:
measure: Study-Related Adverse Events
timeFrame: 6 months
Secondary outcomes:
measure: Quality of Life (QOL) Described by the Patient's Response on the Patient Global Assessment of Severity (PGI-S) Questionnaire
timeFrame: Baseline and 6 months
measure: Quality of Life (QOL) Described by the Patient's Response on the Global Response Assessment (GRA)
timeFrame: 6 months
measure: Quality of Life (QOL) Described by the Patient's Response on the Patient Global Impression of Improvement (PGI-I)
timeFrame: 6 months
Other outcomes:
Locations:
city: Royal Oak
country: United States
facility: Beaumont Hospital - Royal Oak
state: Michigan
city: Royal Oak
country: United States
facility: William Beaumont Hospital
state: Michigan
Study officials:
affiliation: William Beaumont Hospitals
name: Kenneth M Peters, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01748591: Monitoring of Safety and Tolerance of PICOPREP in Clinical Practice
Official title: A Study of PICOPREP in Patients Needing to Clean the Bowel Prior to X-ray Examination, Endoscopy or Surgery
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Bowel Cleanliness
Lead sponsor: Ferring Pharmaceuticals
Sponsor class: INDUSTRY
First posted: 2012-12-12
Enrollment: 3324
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients eligible for endoscopic examination or surgery

Brief summary: A Confirmation of Safety, Tolerance and Efficacy of PICOPREP in Clinical Practice.


Eligibility criteria: Inclusion Criteria:

* Patients eligible for treatment with PICOPREP® for bowel cleansing prior to endoscopic examination or surgery

Exclusion Criteria:

* Patients in which prescription of PICOPREP® is contraindicated

Primary outcomes:
measure: The Frequency of Adverse Events
timeFrame: 2 days
measure: The Severity of Adverse Events
timeFrame: 2 days
Secondary outcomes:
measure: Treatment efficacy measured by assessment of the quality of colon cleaning
timeFrame: 2 days
Other outcomes:
Locations:
city: Benešov
country: Czech Republic
facility: Nemocnice Rudolfa a Stefanie
city: Blansko
country: Czech Republic
facility: Nemocnice Blansko
city: Břeclav
country: Czech Republic
facility: Nemocnice Břeclav
city: Děčín
country: Czech Republic
facility: Děčínská nemocnice
city: Havlíčkův Brod
country: Czech Republic
facility: Nemocnice Havlíčkův Brod
city: Hradec Králové
country: Czech Republic
facility: Fakultní nemocnice Hradec Králové
city: Jablonec nad Nisou
country: Czech Republic
facility: Nemocnice Jablonec
city: Jihlava
country: Czech Republic
facility: Nemocnice Jihlava
city: Jihlava
country: Czech Republic
facility: Privátní GE
city: Olomouc
country: Czech Republic
facility: FN Olomouc
city: Praha 2
country: Czech Republic
facility: Všeobecná fakutlní nemocnice
city: Praha 3
country: Czech Republic
facility: Sanatorium Sv.Anny
city: Praha 4
country: Czech Republic
facility: Privátní GE Praha 4
city: Praha 4
country: Czech Republic
facility: Thomayerova nemocnice
city: Praha 8
country: Czech Republic
facility: FN Bulovka
city: Příbram
country: Czech Republic
facility: Nemocnice Příbram
city: Rumburk
country: Czech Republic
facility: Lužická nemocnice
city: Teplice
country: Czech Republic
facility: Nemocnice Teplice
city: Tábor
country: Czech Republic
facility: Nemocnice Tábor
city: Znojmo
country: Czech Republic
facility: Nemocnice Znojmo
city: Ústí nad Labem
country: Czech Republic
facility: Ústecká poliklinika
city: Česká Lípa
country: Czech Republic
facility: Soukrmá ambulance
Study officials:
affiliation: Ferring Pharmaceuticals
name: Clinical Development Support
role: STUDY_DIRECTOR
References:
Clinical trial NCT06098391: Results at More Than 10 Years of Meniscal Sutures Without Avivement
Official title: Results at More Than 10 Years of Meniscal Sutures Without Avivement
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Knee Arthroscopy
Keywords: knee arthroscopy
Meniscal suture
Meniscal lesion
Meniscectomy
Arthroscopic suturing
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2023-10-24
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult patient (≥18 years old) having medial or lateral meniscal lesion of the knee treated by arthroscopic suture without avivement with or without reconstruction of the anterior cruciate ligament and operated on at the HUS between January 1, 2011 and June 30, 2013

Brief summary: Currently, suturing the lesion is recommended rather than the classic meniscectomy, which leads to early and subsequent gonarthrosis. The most commonly practiced technique is arthroscopic suturing after avivement the area to be sutured to promote healing. But the real benefit of this enhancement has never been documented. The complexity of the surgical procedure makes the acceptability of this indication low by orthopedic surgeons at present (10% sutures compared to 90% meniscectomies).

The aim of the study is to evaluate the 10-year survival rate of meniscal sutures without avivement.


Eligibility criteria: Inclusion Criteria:

* Adult patient (≥18 years old)
* Gender indifferent
* Patient operated on at the HUS between January 1, 2011 and June 30, 2013
* Medial or lateral meniscal lesion of the knee treated by arthroscopic suture without sharpening with or without reconstruction of the anterior cruciate ligament.
* Absence of written opposition in the medical file of the subject (and/or their legal representative if applicable) to the reuse of their data for scientific research purposes.

Exclusion Criteria:

* Subject having expressed his opposition to the reuse of his data for scientific research purposes.
* Subject under judicial protection
* Subject under guardianship or curatorship
* Meniscal lesion not sutured or sutured with sharpening.

Primary outcomes:
measure: 10-year survival rate of meniscal sutures without avivement
timeFrame: 10 years after surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Strasbourg
country: France
facility: Service d'Orthopédie - Traumatologie Membre Supérieur - CHU de Strasbourg - France
Study officials:
References:
Clinical trial NCT03116191: Trial of SK-1404 for Nocturia Due to Nocturnal Polyuria in Japanese Subjects
Official title: Trial of SK-1404 for Nocturia Due to Nocturnal Polyuria in Japanese Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Nocturia Due to Nocturnal Polyuria
Lead sponsor: Sanwa Kagaku Kenkyusho Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2017-04-14
Enrollment: 125
Sex: ALL
Minimum age (years): 55
Maximum age (years): 79
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this trial is to demonstrate efficacy of SK-1404 against placebo for the treatment of subjects with nocturia due to nocturnal polyuria, during 4 weeks of treatment.


Eligibility criteria: Inclusion Criteria:

* 5 \> nocturnal voids ≥2
* NPI \>0.33

Exclusion Criteria:

* Polydipsia
* Cardiac failure
* Syndrome of inappropriate antidiuretic hormone secretion
* Hyponatraemia
* Uncontrolled diabetes mellitus
* Uncontrolled hypertension
* Moderate or severe over-active bladder (OAB)
* Severe benign prostate hyperplasia (BPH)
* Sleep apnoea
* Interstitial cystitis
* Stress urinary incontinence
* Diabetes insipidus
* Complication or a history of urological cancer

Primary outcomes:
measure: Change from baseline in mean number of nocturnal voids
timeFrame: 4 weeks
Secondary outcomes:
measure: Change from base line in mean nocturnal urine volume
timeFrame: 4 weeks
measure: Change from base line in mean time to first awakening to void
timeFrame: 4 weeks
measure: Change from base line in mean Nocturnal Polyuria Index (NPI)
timeFrame: 4 weeks
measure: Change from base line in the score of Nocturia-Specific Quality-of-Life Questionnaire (N-QoL)
timeFrame: 4 weeks
Other outcomes:
Locations:
city: Tokyo
country: Japan
facility: Investigational site (there may be other sites in this country)
Study officials:
References:
Clinical trial NCT05473091: Is There a Link Between Inflammation and Endocrinopathies in Turner Syndrome?
Official title: Is There a Link Between Inflammation and Endocrinopathies in Turner Syndrome?
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Turner Syndrome
Lead sponsor: Central Hospital, Nancy, France
Sponsor class: OTHER
First posted: 2022-07-25
Enrollment: 179
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 56
Standard ages: ADULT
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Retrospective analysis of data from patients followed in the Service of Endocrinology, Diabetology and Nutrition, University Hospital of Nancy

Brief summary: Liver abnormalities are common in Turner syndrome. The physiopathology of these abnormalities is unknown for the moment but their potentially serious evolution requires additional explorations.


Eligibility criteria: Inclusion Criteria Experimental group:

* Turner syndrome

Inclusion Criteria Control group:

* healthy subjects

Primary outcomes:
measure: pro inflammatory score
timeFrame: 18 years
Secondary outcomes:
Other outcomes:
Locations:
city: Nancy
country: France
facility: CHUR de Nancy
Study officials:
References:
Clinical trial NCT03906591: Crestal Bone Level After Allogenic Bone Ring With Simultaneous Dental Implant Placement
Official title: Evaluation Of Crestal Bone Level After Alveolar Bone Augmentation of Atrophied Posterior Mandibular Region Using Allogenic Bone Rings Vs. Autogenous Bone Rings With Simultaneous Dental Implant Placement (A Randomized Controlled Clinical Trial)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Allogenic Bone Ring
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2019-04-08
Enrollment: 28
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This trial is aiming to answer a question whether in Patients with severely atrophied, distal mandibular regions, the use of allogenic bone rings with simultaneous dental implants, compared to autogenous bone rings, give successful clinical and radiographic outcomes without donor site morbidity


Eligibility criteria: Inclusion Criteria:

1. Medically free form any systemic diseases that contraindicate the surgical procedures or affect predictable outcomes and non-smoker subjects.
2. Atrophic mandibular distal region requiring vertical augmentation.
3. Good oral hygiene and healthy keratinized mucosa.

Exclusion Criteria:

1. Presence of acute dentoalveolar infection or any pathologic lesions.
2. Totally edentulous patients and patients requiring massive reconstruction and augmentation procedures.
3. Patients with history of previously failed augmentation procedures, or failed implant placement at the intended augmentation region.

Primary outcomes:
measure: change in crestal bone height
timeFrame: at 6 months
Secondary outcomes:
measure: graft failure
timeFrame: after 1 week, 6 months and after 9 months
measure: implant loss
timeFrame: after 1 week, 6 months and after 9 months
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00263991: Cortical Reorganisation in Patients With Primary Headache Disorders
Official title: Cortical Reorganisation in Patients With Primary Headache Disorders
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Migraine Without Aura
Chronic Tension-Type Headache
Lead sponsor: Danish Headache Center
Sponsor class: OTHER
First posted: 2005-12-12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: OTHER

Brief summary: Primary headache disorders are now accepted as physiological diseases, and advanced imaging-techniques have demonstrated a migraine generator in the brain stem and increased stimulus sensitivity in these patients. The underlying neuronal dysfunctions remain to to clarified and the existing neurophysiological methods have not yet been useful. More sensitive and reliable methods are therefore highly needed. The aims of the study are therefore to develop a sensitive and reliable method to demonstrate a cortical reorganisation and expansion of pain sensitive cortical areas in patients with migraine or tension-type headache.


Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis og migraine without aura or chronic tension-type headache

Exclusion Criteria:

* serious somatic or psychiatric diseases including depression
* overuse of analgesics
* regular intake of opiates or benzodiazepines
* intake of prophylactic headache medication
* pregnancy

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Glostrup, Copenhagen
country: Denmark
facility: Danish Headache Center; Department of Neurology, Glostrup Hospital, University of Copenhagen
Study officials:
affiliation: Danish Headache Center, Department of Neurology, Glostrup Hospital, University of Copenhagen, Denmark
name: Lars Bendtsen, MD, Ph.d
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02395991: Evaluation of Transient Dyspnea During Gadoxetic Acid Enhanced Multiphasic Liver MRI
Official title: Evaluation of Transient Dyspnea During Gadoxetic Acid Enhanced Multiphasic Liver MRI
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Dyspnea
Keywords: gadoxetic acid
transient dyspnea
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
Collaborators: name: Bayer
First posted: 2015-03-24
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who are referred to MR unit for hepatocyte-specific contrast enhanced liver MRI using gadoxetic acid.

Brief summary: The purpose of this study is to observe transient dyspnea pattern after Gd-EOB-DTPA administration by obtaining continuous dynamic T1 weighted image data.


Eligibility criteria: Inclusion Criteria:

* Patients who are referred to MR unit for hepatocyte-specific contrast enhanced liver MRI using gadoxetic acid, to characterize focal liver lesion or to investigate diffuse liver disease
* OR, Liver living donor candidates
* AND subjects who sign the informed consent.

Exclusion Criteria:

* Minors under 18 years old
* All contraindication to MRI
* Hypersensitivity to Gd
* Biliary obstruction

Primary outcomes:
measure: Number of Participants With Transient Dyspnea.
timeFrame: during 3 minutes after contrast media administration
Secondary outcomes:
measure: Duration of Transient Dyspnea in Participants With Transient Dyspnea.
timeFrame: during 3 minutes after contrast media administration
Other outcomes:
measure: Liver Stiffness Value
timeFrame: in three days after MRI
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
Study officials:
affiliation: Seoul National University Hospital
name: Jeong Min Lee, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06682091: Management and Outcome of Mesh Infection After Abdominoplasty in a Tertiary Care Centre
Official title: Management and Outcome of Mesh Infections After Abdominoplasty in a Tertiary Care Center in France
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Abdominal Infection
Keywords: mesh infection
abdominoplasty
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2024-11-12
Enrollment: 209
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Subjects taken in care for abdominal mesh infection in the Hospices Civils de Lyon from 2010 to 2023.

Brief summary: Hernia repair is among most frequent surgical interventions. The use of abdominal mesh in hernia repair has become the Gold Standard strategy, reducing the risk of relapse.

The mesh infection risk is estimated lower than 1% in simple situations, but can increase up to 20% in complicated patients. Risk factors are well known, but we lack data regarding the therapeutic strategies and outcomes.

This study aims to describe the characteristics and management of abdominal mesh infections, and the related outcomes.


Eligibility criteria: Inclusion Criteria:

* parietal mesh infection
* age \> 18

Exclusion Criteria:

* Non French speaking patients.
* Persons under tutorship or curatorship.

Primary outcomes:
measure: Treatment failure.
timeFrame: Retrospective analysis from initial treatment to any treatment failure within 2010 to 2023
Secondary outcomes:
Other outcomes:
Locations:
city: Lyon
country: France
facility: Hospices Civils de Lyon - Hopital de la Croix Rousse - Centre de reference des infection ostéo-articulaires de Lyon
Study officials:
References:
Clinical trial NCT04928391: A Single Bolus of Dexmedetomidine Versus Nalbuphine in Postoperative Agitation
Official title: Optic Nerve Sheath Diameter (ONSD): A New Modality to Assess Postoperative Agitation After a Single Bolus of Dexmedetomidine Versus Nalbuphine in Children With Cleft Palate Repair
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE3
Conditions: Cleft Palate
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2021-06-16
Enrollment: 90
Sex: ALL
Minimum age (years): 1
Maximum age (years): 7
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The hypothesis of this study is to investigate and compare the efficacy between the administrations of single intravenous (IV) dose of dexmedetomidine versus nalbuphine in preventing immediate postoperative agitation in children undergoing cleft palate repair.

Detailed description: A written informed consent will be taken from the guardian of children.Patients will be assigned randomly to three groups (30 subjects each) to be anesthetized. The study drug will be delivered in opaque bags labeled "study drug" and 90 patients will be allocated in three groups (of 30 patients each) to receive the study drug at the end of surgery; a single dose of 0.5 µ/kg IV dexmedetomidine (Group D) or a single dose of 0.1 mg/kg IV nalbuphine (Group N) or same volume of saline placebo (Group C).

Eligibility criteria: Inclusion Criteria:

* Children (age 1-7 years) of American Society of Anaesthesiologists physical status (ASA) I-II
* Elective cleft palate repair ± cleft lip surgery under general anesthesia.

Exclusion Criteria:

* Ventriculo-peritoneal shunt
* Suspected meningitis
* Congenital hydrocephalus
* Clinical signs of suspected increased intracranial pressure
* On treatment for seizures or metabolic diseases
* Children with developmental delay
* Hypersensitivity to dexmedetomidine or nalbuphine

Primary outcomes:
measure: the Pediatric Anesthesia Emergence Delirium (PAED) score
timeFrame: 1 hour postoperative
Secondary outcomes:
measure: FLACC (Face, Legs, Activity, Cry, and Consolability) pain score.
timeFrame: 1 hour postoperative
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Omar Soliman
state: Assuit
city: Assiut
country: Egypt
facility: Assiut university hospital
Study officials:
affiliation: Assiut University
name: Omar Soliman
role: STUDY_DIRECTOR
References:
citation: Milic M, Goranovic T, Knezevic P. Complications of sevoflurane-fentanyl versus midazolam-fentanyl anesthesia in pediatric cleft lip and palate surgery: a randomized comparison study. Int J Oral Maxillofac Surg. 2010 Jan;39(1):5-9. doi: 10.1016/j.ijom.2009.09.007. Epub 2009 Oct 24.
Clinical trial NCT02432391: Lifestyle Modification for Type 2 Diabetes Involving Reduction of After-meal Blood Glucose Elevations
Official title: Self-Monitoring of Blood Glucose (SMBG) as an Educational Tool and a Negative Feedback Loop to Reinforce Blood Glucose Lowering and Discourage Blood Glucose Elevating Self-Management Behaviors in Adults With T2DM
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diabetes Mellitus, Type 2
Lead sponsor: University of Virginia
Sponsor class: OTHER
Collaborators: name: LifeScan
First posted: 2015-05-04
Enrollment: 47
Sex: ALL
Minimum age (years): 24
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine if a lifestyle modification program (GEM) that focuses on reducing after-meal blood glucose elevations can improve blood glucose control in people with type 2 diabetes. Half of the participants will continue their routine medical care, and half will receive five sessions of GEM in addition to their routine care. The two groups will be assessed using diabetes-relevant medical, behavioral and psychological measures.


Eligibility criteria: Inclusion Criteria:

* Diagnosed with type 2 diabetes within the past 5 years
* Age \>24 and \<80 years
* HbA1c \>7.0%
* Approval of primary care physician to participate

Exclusion Criteria:

* Currently using, or used within the last 3 months, medications that directly lower BG (e.g., insulin, sulfonylureas, glinides, or DPP-4 inhibitors).
* Currently using, or used within the last 3 months, thiazides at doses above HCTZ 25 mg or equivalent, or loop diuretics above furosemide 20mg or equivalent.
* Currently pregnant or contemplating pregnancy in the coming year
* Currently using, or used within the last 3 months, medications that impede weight loss (e.g., prednisone)
* Having conditions that preclude increasing physical activity, e.g. severe neuropathy, active cardiovascular disease, emphysema, osteoarthritis, stroke.
* Undergoing cancer treatment
* History of lactic acidosis
* Diagnosed with renal impairment

Primary outcomes:
measure: Change from baseline glycosylated hemoglobin at 6 months
timeFrame: 0 and 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Charlottesville
country: United States
facility: University of Virginia
state: Virginia
Study officials:
affiliation: University of Virginia
name: Daniel Cox, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Cox DJ, Fang K, McCall AL, Conaway MR, Banton TA, Moncrief MA, Diamond AM, Taylor AG. Behavioral Strategies to Lower Postprandial Glucose in Those with Type 2 Diabetes May Also Lower Risk of Coronary Heart Disease. Diabetes Ther. 2019 Feb;10(1):277-281. doi: 10.1007/s13300-018-0554-6. Epub 2018 Dec 18.